Therefore, researchers are exploring various strategies, such as combining CAR‐T cells with PD‐1/PD‐L1 antibodies to inhibit the PD1/PD‐L1 signaling‐induced immunosuppression.[47] In addition to inhibiting PD‐1/PD‐L1 signaling, the local administration or genetic modification of CAR‐T cells with chemokines, such as CXCR2 or CXCR1, can enhance the migration and infiltration of CAR‐T cells into solid tumors.[48] Enzymes‐engineered CAR‐T cells are also being developed to degrade the extracellular matrix of tumor stroma for improved infiltration and anti‐tumor effect. The gene discussed is PDCD1; the disease is neoplasm.